Purity
Greater than 90% as determined by SDS-PAGE.
Research Area
Developmental Biology
Alternative Names
ELAV (embryonic lethal, abnormal vision, Drosophila) like 3 (Hu antigen C); ELAV (embryonic lethal, abnormal vision, Drosophila) like 4 (Hu antigen D); ELAV like 3; ELAV like 4; ELAV like neuron specific RNA binding protein 3; ELAV like neuron specific RNA binding protein 4; ELAV like protein 3; ELAV like protein 4; ELAV-like protein 3; ELAV3_HUMAN; Elavl3; ELAVL4; Hu antigen C; Hu antigen D; Hu-antigen C; HuC; HUCL; HuD; Paraneoplastic cerebellar degeneration-associated antigen; Paraneoplastic encephalomyelitis antigen HuD; Paraneoplastic limbic encephalitis antigen 21; PLE21; PNEM
Species
Homo sapiens (Human)
Expression Region
1-367aa
Target Protein Sequence
MVTQILGAMESQVGGGPAGPALPNGPLLGTNGATDDSKTNLIVNYLPQNMTQDEFKSLFGSIGDIESCKLVRDKITGQSLGYGFVNYSDPNDADKAINTLNGLKLQTKTIKVSYARPSSASIRDANLYVSGLPKTMSQKEMEQLFSQYGRIITSRILVDQVTGVSRGVGFIRFDKRIEAEEAIKGLNGQKPLGAAEPITVKFANNPSQKTGQALLTHLYQSSARRYAGPLHHQTQRFRLDNLLNMAYGVKSPLSLIARFSPIAIDGMSGLAGVGLSGGAAGAGWCIFVYNLSPEADESVLWQLFGPFGAVTNVKVIRDFTTNKCKGFGFVTMTNYDEAAMAIASLNGYRLGERVLQVSFKTSKQHKA
Note: The complete sequence including tag
sequence, target protein sequence and linker sequence could be provided upon request.
Protein Length
Full Length
Tag Info
N-terminal 6xHis-tagged
Form
Liquid or Lyophilized powder
Note: We will preferentially ship the format that
we have in stock, however, if you have any special requirement for the format, please remark your
requirement when placing the order, we will prepare according to your demand.
Buffer
If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol.
Note: If you have any special requirement for the
glycerol content, please remark when you place the order.
If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer,
6% Trehalose, pH 8.0.
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%. Customers could use it as reference.
Storage Condition
Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw
cycles.
Shelf Life
The shelf life is related to many factors, storage state, buffer ingredients, storage temperature
and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized
form is 12 months at -20°C/-80°C.
Lead Time
3-7 business days
Notes
Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet & COA
Please contact us to get it.
Description
The expression region of this recombinant Human ELAVL3 covers amino acids 1-367. This ELAVL3 protein is theoretically predicted to have a molecular weight of 41.5 kDa. This protein is generated in a yeast-based system. The ELAVL3 gene fragment has been modified by fusing the N-terminal 6xHis tag, providing convenience in detecting and purifying the recombinant ELAVL3 protein during the following stages.
Human ELAV-like protein 3 (ELAVL3), a member of the ELAVL protein family, binds to RNA molecules and influences their processing, stability, and translation. ELAVL3 is predominantly expressed in neurons, highlighting its role in neuronal development and function. It is involved in the regulation of RNA metabolism in the nervous system. ELAVL3 participates in the regulation of alternative splicing, influencing the diversity of mRNA isoforms produced in neurons. This activity can impact protein diversity and function. ELAVL3 has been implicated in neuronal differentiation and maintenance of the neuronal phenotype. Its expression is often associated with developing and mature neurons. Dysregulation of ELAVL3 has been linked to neurodevelopmental disorders and neurological diseases, making them potential targets for therapeutic interventions.
